 "BSE to discontinue trading in Ranbaxy from April 6")
After Ranbaxy's merger with Sun Pharma, the scrip will be discountinued from trading on the bourses, while Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy, the BSE said in a statement today.
BSE will include Bosch Ltd in S&P BSE 100, Gujarat Gas Co Ltd in S&P BSE 200 and Global Offshore Services in S&P BSE 500, replacing Ranbaxy from April 6, the BSE statement said.
The BSE has also decided to include AGI Infra and Mahabir Metallex in S&P BSE SME IPO indices effective from March 30, the statement said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%